Recombinant Technologies, LLC

CHESHIRE, CT 06410

SBIR Award Summary

Total Number of Awards 10
Total Value of Awards $2.99MM
First Award Date 07/01/01
Most Recent Award Date 09/30/17

Key Personnel

Last Name Name Awards Contact
Sundaram Pazhani Sundaram 10

10 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-287
Budget: 09/30/17 - 04/30/18

? DESCRIPTION (provided by applicant): Alzheimer's disease [AD] represents a progressive degenerative illness that affects the brain, resulting in memory impairment. The complex etiology of AD is not fully resolved, although toxic isoforms of amyloid-? (A?) plaques are strongly implicated. Current treatment options are considered to be sympto...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 09/01/17 - 02/28/18

Abstract Alzheimer?s disease (AD) is the most common cause of dementia among elderly patients afflicted by neurodegenerative diseases, affecting about 25 million people worldwide and regarded as the fourth most common cause of death. Significant accumulation in the brain of Amyloid ? (A?) is consistently observed in AD. Due to its accumulation i...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 05/01/17 - 04/30/18

? DESCRIPTION (provided by applicant): Alzheimer's disease [AD] represents a progressive degenerative illness that affects the brain, resulting in memory impairment. The complex etiology of AD is not fully resolved, although toxic isoforms of amyloid-? (A?) plaques are strongly implicated. Current treatment options are considered to be sympto...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-088
Budget: 05/15/16 - 04/30/17

? DESCRIPTION (provided by applicant): Alzheimer's disease [AD] represents a progressive degenerative illness that affects the brain, resulting in memory impairment. The complex etiology of AD is not fully resolved, although toxic isoforms of amyloid-? (A?) plaques are strongly implicated. Current treatment options are considered to be symptom...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 09/01/10 - 06/30/12

DESCRIPTION (provided by applicant): ABSTRACT The objective of our research is to develop an effective therapy for Alzheimer's disease (AD), by using an approach that is able to concentrate, bind and eliminate -amyloid peptides and thereby delay and or halt deposition of plaque in the brain. We have previously developed and demonstrated a...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 05/01/08 - 10/31/09

DESCRIPTION (provided by applicant): The hallmark of Alzheimer's disease (AD) is the presence in brain of plaques, which are complex extracellular lesions composed of a central deposition of 2-amyloid peptide. Genetic, neuropathological and biochemical evidence have shown that these deposits play an important role in the pathogenesis of AD. We h...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/06 - 05/31/08

DESCRIPTION (provided by applicant): The neurotoxic amyloid plaques in the brain, characteristic of Alzheimer's disease (AD), are formed by aggregation of 2 overlapping fragments (AB1-40 and AB1-42) of the amyloid precursor protein. These A-beta peptides can cross the blood-brain barrier. Our long-term goal is to develop an effective therapy fo...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/15/05 - 05/31/06

DESCRIPTION (provided by applicant): The neurotoxic amyloid plaques in the brain, characteristic of Alzheimer's disease (AD), are formed by aggregation of 2 overlapping fragments (AB1-40 and AB1-42) of the amyloid precursor protein. These A-beta peptides can cross the blood-brain barrier. Our long-term goal is to develop an effective therapy fo...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/03 - 05/31/04

DESCRIPTION (provided by applicant): The long-term goal is to develop an effective therapy for Alzheimer's disease, by using a subcutaneous hydrogel to recognize, concentrate and eliminate beta-amyloid (Abeta) peptides and thereby halt deposition of plaque in the brain. The hydrogel forms in situ from an injected solution within about 1 minute ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/01 - 03/31/03

DESCRIPTION (provided by applicant): Protein-protein interactions are central to the process of signal transduction in biological systems. Transmembrane receptor tyrosine kinase (RTKs) play important roles in many aspects of cell growth and behavior. Activated RTKs, including one of the well-studied PDGF-be...

Load More